I'm looking at that trial too, among others, we'll compare notes...best of luck...
Ribavirin is teratogenic, meaning it can cause birth defects. Because of its long half life, TWO types of contraceptives are generally recommended during treatment and for six months following treatment.
As to the study, you might inquire what your projected chances are with either the control (non Albu) group, or the low-dose Albu group -- compared to either the high-dose Albu group or individualized therapy using SOC (standard of care).
With SOC, the treatment potentially would be more individualized with more of a doctor-patient data exchange since it would be unblinded. Also, there's the issue of rescue drugs which are used in SOC but not sure in your trial. You should be aware that a different new drug is in trial called Telaprevir (VX-950) that is showing a lot of promise. Another NY doctor, Dr. Ira Jacbosen is one of the lead investigators with that drug.
All the best,
-- Jim